Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities ageing of the immune system
The specific objectives of HEP-CAR will be achieved in the following collaborative work packages:
Objective 1. To identify genetic alterations and aberrant host signalling pathways in HCC associated with different comorbidities.
Outcome: Identify co-morbidity specific signalling signatures that relate to clinical parameters [WP1].
Objective 2. To identify lipid biomarkers for HCC and associated co-morbidities.
Outcome: To identify co-morbidity specific lipid signatures that relate to genetic and clinical parameters [WP2].
Objective 3. To identify the effect of viral co-morbidities on HCC-disease pathways.
Outcome: To discover HBV and HCV specific pathways of HCC and relate to genetic and clinical parameters [WP3].
Objective 4. To identify the immune pathways contributing to the progression and control of HCC with respect to specific co-morbidities.
Outcome: To discover immune markers defining HCC progression and the impact of co-morbidities [WP4].
Objective 5. To validate the HCC-disease pathways and their relevance to co-morbidities and patient response to therapy.
Outcome: To corroborate and specify those markers that can be used 1) to predict HCC outcome and 2) patient response to therapy [WP5].
Objective 6. To transform the treatment of HCC by promoting a unified approach to personalized HCC management and to communicate this information in Europe through an integrated HEP-CAR classification system.